MediciNova presents results from subgroup analysis of Phase 2 study of MN-001

MediciNova announced that its Chief Medical Officer, Kazuko Matsuda, presented positive results from a subgroup analysis of the completed Phase 2 clinical trial which evaluated MN-001 for the treatment of hypertriglyceridemia at the International Diabetes Federation World Diabetes Congress 2022 held online December 5 – 8. In the completed Phase 2 study, MN-001 significantly reduced serum triglycerides in participants with non-alcoholic fatty liver disease and hypertriglyceridemia. Subsequent in vitro results revealed that MN-001, or tipelukast, downregulated CD36 and upregulated ABCG1 mRNA expression, both of which are highly associated with Type 2 diabetes mellitus. Hypothesizing that MN-001 might be more effective at reducing serum triglycerides in participants with a dual diagnosis of NAFLD and Type 2 diabetes mellitus, a subgroup analysis was conducted in participants with and without T2DM. Compared to subjects without T2DM, the T2DM group showed a greater reduction in serum triglyceride levels at Week 8, 50.8% reduction for with T2DM versus 17.8% reduction for without T2DM, p=0.098.